Leerink Partners analyst Andrew Berens maintained a Hold rating on Agios Pharma (AGIO – Research Report) on January 6. The company’s shares ...

Fintel reports that on January 8, 2025, Leerink Partners downgraded their outlook for Accolade (NasdaqGS:ACCD) from ...

D. Boral Capital reaffirmed their buy rating on shares of Compass Therapeutics (NASDAQ:CMPX – Free Report) in a research report sent to investors on Wednesday morning,Benzinga reports. D. Boral ...

Walgreens Boots Alliance beat analysts' lowered expectations for first-quarter profit and maintained its annual forecast on ...

Leerink Partners has recently reduced CureVac BV (CVAC) stock to Market Perform rating, as announced on April 25, 2024, according to Finviz. Earlier, on June 8, 2023, SVB Securities had initiated the ...

Investment analysts at Zacks Research cut their FY2025 earnings estimates for Zoetis in a research report issued on Wednesday ...

Fintel reports that on January 6, 2025, Leerink Partners upgraded their outlook for Align Technology (NasdaqGS:ALGN) from ...

On second thought, the FDA figures it no longer needs to discuss Exelixis’ application for Cabometyx in neuroendocrine tumors ...

CureVac BV (CVAC) stock saw a modest uptick, ending the day at $4.44 which represents a slight increase of $0.82 or 22.65% from the prior close of $3.62. The stock opened at $4.14 and touched a low of ...

In a report released on January 3, Whit Mayo from Leerink Partners maintained a Buy rating on OceanPal Inc (OP – Research Report). The ...

Alongside plans to spin out a new company, the Belgian drugmaker said it will cut some 300 positions, or about 40% of its ...

Wells Fargo & Co. has hired health-care banker Michael Giaquinto as a managing director focused on the medical technology sector from Leerink Partners, according to a person briefed on the matter.